Filtered By:
Condition: Ischemic Stroke
Drug: Plavix

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 1287 results found since Jan 2013.

PIAST - Platelet Inhibition Assessment in Stroke Trial - The Assessment of Efficacy of Platelet Aggregation Inhibition in Stroke Patients with the Multiplate Analyzer, a Point-of-Care Method (P02.055)
CONCLUSIONS: This trial demonstrates that nearly 1/3 of cerebral ischemia patients are potential aspirin nonresponders, which might have significant implications in the medical treatment of stroke patients.Supported by: Multiplate analyzer(c) placed to our disposal for the trial formerly by Dynabite (Munich, Germany) now by Roche Pharmaceuticals.Disclosure: Dr. Menon has nothing to disclose. Dr. Jun has nothing to disclose. Dr. Meyding-Lamadé has nothing to disclose. Dr. Grabowski has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Menon, S., Jun, T., Meyding-Lamade, U., Grabowski, A. Tags: P02 Cerebrovascular Disease II Source Type: research

Early Dual versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack: An Updated Systematic Review and Meta-Analysis.
CONCLUSIONS: For patients with acute non-cardioembolic ischemic stroke or TIA, dual therapy was more effective than monotherapy in reducing risks of early recurrent stroke. The results of the CHANCE study are consistent with previous studies done in other parts of the world. PMID: 24030500 [PubMed - as supplied by publisher]
Source: Circulation - September 12, 2013 Category: Cardiology Authors: Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, Markus HS, Gorelick PB, Liu L, Lin W, Wang Y Tags: Circulation Source Type: research

Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
CONCLUSIONS: The available trial evidence showed that, for individuals with acute ischaemic stroke, GP IIb-IIIa inhibitors are associated with a significant risk of intracranial haemorrhage with no evidence of any reduction in death or disability in survivors. These data do not support their routine use in clinical practice. The conclusion is driven by trials of Abciximab, which contributed 89% of the total number of study participants considered. PMID: 24609741 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - March 8, 2014 Category: Journals (General) Authors: Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I Tags: Cochrane Database Syst Rev Source Type: research

Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention
In conclusion, in patients with coronary artery disease undergoing PCI, the presence of HPR to adenosine diphosphate is a risk factor for stroke.
Source: The American Journal of Cardiology - March 17, 2014 Category: Cardiology Authors: Nevio Taglieri, Maria Letizia Bacchi Reggiani, Tullio Palmerini, Gabriele Ghetti, Francesco Saia, Pamela Gallo, Carolina Moretti, Gianni Dall'Ara, Cinzia Marrozzini, Antonio Marzocchi, Claudio Rapezzi Tags: Coronary Artery Disease Source Type: research

Dual antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack: pros and cons.
Authors: Hong KS Abstract Dual antiplatelet therapy simultaneously blocks different platelet activation pathways and might thus be more potent at inhibiting platelet activation and more effective at reducing major ischemic vascular events compared to antiplatelet monotherapy. Aspirin plus clopidogrel dual therapy is now the standard therapy for patients with acute coronary syndrome and for those undergoing percutaneous coronary intervention. However, dual antiplatelet therapy carries an increased risk of bleeding. Patients with ischemic stroke or transient ischemic attack (TIA) are generally older and likely to hav...
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research

Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
CONCLUSIONS: CYP2C19*2 and CYP2C19*3 had a significant impact on clopidogrel response, but was not associated with ischemic events during 1 year of follow-up in patients with acute ischemic stroke. HPR was an independent risk factor for ischemic events, and the VerifyNow P2Y12 test may be available to guide individualized antiplatelet therapies in stroke patients in China. PMID: 26177117 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - July 15, 2015 Category: Neuroscience Authors: Han Y, Lv HH, Liu X, Dong Q, Yang XL, Li SX, Wu S, Jiang JM, Luo Z, Zhu DS, Zhang Y, Zheng Y, Guan YT, Xu JF Tags: CNS Neurosci Ther Source Type: research

Dual Antiplatelet Therapy with Clopidogrel and Aspirin for Secondary Stroke Prevention
This article aims at providing a comprehensive review of the evidence on the use of aspirin plus clopidogrel for secondary stroke prevention, with special focus on important studies that may impact clinical practice of treating patients with stroke or transient ischemic attack.
Source: Current Cardiology Reports - August 20, 2015 Category: Cardiology Source Type: research

Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
CONCLUSION: Currently available evidence does not substantiate the widespread use of long-term aspirin with clopidogrel for the secondary prevention of ischemic stroke or TIA. PMID: 26386103 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - September 21, 2015 Category: Drugs & Pharmacology Authors: Davis KA, Miyares MA, Dietrich E Tags: Am J Health Syst Pharm Source Type: research

Safety of percutaneous coronary intervention in patients with acute ischemic stroke/transient ischemic attack and acute coronary syndrome
Conclusions The primary and secondary end points were not enhanced in patients undergoing PCI. Therefore PCI is safe in patients with stroke/TIA and concomitant ACS.
Source: Clinical Research in Cardiology - October 29, 2015 Category: Cardiology Source Type: research

Antiplatelet treatment in stroke: new insights.
CONCLUSIONS: Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke or transient ischemic attack. Moreover, clinicians should carefully assess the pros and cons in each case and individualize the need for prolonged dual antiplatelet therapy. PMID: 27291399 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 8, 2016 Category: Drugs & Pharmacology Authors: Milionis H, Liontos A, Vemmos K, Spengos K Tags: Curr Pharm Des Source Type: research

Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
This article focuses on three randomised controlled trials (RCTs) that are investigating the utility of rivaroxaban, a direct, oral, factor Xa inhibitor, in additional areas of stroke prevention where data for anticoagulants are lacking: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment (PIONEER AF-PCI); New Approach riVaroxoban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS); and Global study comparing a rivAroxaban-based antithrombo...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Hemmrich M, Peterson ED, Thomitzek K, Weitz JI Tags: Thromb Haemost Source Type: research

Evaluation of Antithrombotic Bridging Methods in Acute Ischemic Stroke Patients with Atrial Fibrillation (P6.281)
Conclusions:Preliminary data supports against bridging with parenteral anticoagulation in acute ischemic stroke and AF, with a higher incidence of complications observed overall. Higher incidence of extracranial complications observed with bridging anticoagulation and higher incidence of intracranial complications observed from bridging antiplatelet therapy. This finding may be related to the limited number of patients included. A future goal for this project will be to expand the number of charts reviewed to strengthen the validity of these results.Disclosure: Dr. Swafford has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Swafford, K., Lee, J. Tags: Prevention of Cerebrovascular Disease Source Type: research

Genetic signatures in ischemic stroke: Focus on aspirin resistance.
Abstract Stroke is one of the leading causes of death. There has been compelling evidence that stroke has a genetic component. Genetic variants not only influence susceptibility to stroke but have also been found to alter the response to pharmacological agents and influence the clinical outcome of the disease. Stroke patients are treated with antiplatelet drugs like aspirin and clopidogrel to prevent a secondary stroke. Inspite the fact that many new antiplatelet drugs have been developed; aspirin is still considered as a golden standard for the antiplatelet therapy. Aspirin achieves its action by inhibiting plate...
Source: CNS and Neurological Disorders Drug Targets - October 2, 2017 Category: Drugs & Pharmacology Authors: Munshi A, Vasudeva K, Chaurasia P, Singh S Tags: CNS Neurol Disord Drug Targets Source Type: research

Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials
ConclusionPFO closure results in a significant reduction in the recurrence of ischemic stroke compared to medical therapy alone, primarily antiplatelet, among cases with PFO and cryptogenic stroke.
Source: Journal of Neurology - January 22, 2018 Category: Neurology Source Type: research

The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin.
Abstract Atherosclerosis is a chronic and progressive disease of the arterial walls and a leading cause of non-cardioembolic ischemic stroke. P2Y12 is a well-recognized receptor that is expressed on platelets and is a target of thienopyridine-type antiplatelet drugs. In the last few decades, P2Y12 receptor inhibitors, such as clopidogrel, have been applied for the secondary prevention of non-cardioembolic ischemic stroke. Recent clinical studies have suggested that these P2Y12 receptor inhibitors may be more effective than other antiplatelet drugs in patients with ischemic stroke/transient ischemic attack of ather...
Source: Cellular and Molecular Life Sciences : CMLS - October 9, 2018 Category: Cytology Authors: Gao Y, Yu C, Pi S, Mao L, Hu B Tags: Cell Mol Life Sci Source Type: research